New Treatments & Clinical Trials for Becker Muscular Dystrophy

Becker muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle weakness that typically begins in the legs and pelvis during childhood or adolescence. It affects about 1 in 18,000 to 30,000 males and follows a milder course than Duchenne muscular dystrophy. Treatment focuses on managing symptoms, preserving mobility, and monitoring heart and breathing function.

What's actually going on in research

Trials are testing gene therapies that deliver functional dystrophin genes, exon-skipping drugs that help cells make more usable dystrophin protein, and anti-inflammatory drugs that may slow muscle damage. Researchers are also studying heart-protective therapies, since cardiomyopathy is a leading concern, and ways to predict disease progression based on specific mutations.

What to know before you search

Eligibility typically depends on confirmed dystrophin gene mutation, age, current muscle function, heart status, and whether the specific mutation matches the therapy being tested.

What types of trials are currently open

• Gene therapy trials — Testing one-time infusions of viral vectors carrying dystrophin genes to see if the body can produce the missing protein.
• Exon-skipping trials — Testing drugs that alter how cells read the dystrophin gene, aiming to produce more functional protein.
• Cardiac trials — Testing medications and interventions to protect heart function and prevent cardiomyopathy.
• Anti-inflammatory trials — Testing drugs that may reduce inflammation and slow muscle breakdown.
• Natural history studies — Following people with Becker muscular dystrophy over time to understand how the disease progresses and what factors predict outcomes.